{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:05:15Z","timestamp":1777352715188,"version":"3.51.4"},"reference-count":66,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T00:00:00Z","timestamp":1386979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Heart Fail"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:p>Clinical trials have demonstrated morbidity and mortality benefits of mineralocorticoid receptor antagonists (<jats:styled-content style=\"fixed-case\">MRAs<\/jats:styled-content>) in patients with heart failure. These studies have used either spironolactone or eplerenone as the<jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>. It is generally believed that these two agents have the same effects, and the data from studies using one drug could be extrapolated for the other. National and international guidelines do not generally discriminate between spironolactone and eplerenone, but strongly recommend using an<jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>for patients with heart failure due to<jats:styled-content style=\"fixed-case\">LV<\/jats:styled-content>systolic dysfunction and post\u2010infarct<jats:styled-content style=\"fixed-case\">LV<\/jats:styled-content>systolic dysfunction. There are no major clinical trials directly comparing the efficacy of these two drugs. This article aims to compare the pharmacokinetics and pharmacodynamics of spironolactone and eplerenone, and to analyse the available data for their cardiovascular indications and adverse effects. We have also addressed the role of special circumstances including co\u2010morbidities, concomitant drug therapy, cost, and licensing restrictions in choosing an appropriate<jats:styled-content style=\"fixed-case\">MRA<\/jats:styled-content>for a particular patient, thus combining an evidence\u2010based approach with personalized medicine.<\/jats:p>","DOI":"10.1111\/ejhf.31","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T17:48:53Z","timestamp":1391449733000},"page":"143-150","source":"Crossref","is-referenced-by-count":29,"title":["Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure"],"prefix":"10.1111","volume":"16","author":[{"given":"Javaid","family":"Iqbal","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Science at the University of Sheffield and Cardiology Department at Sheffield Teaching Hospitals NHS Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasir","family":"Parviz","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Science at the University of Sheffield and Cardiology Department at Sheffield Teaching Hospitals NHS Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre University of Michigan Ann Arbor MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Newell\u2010Price","sequence":"additional","affiliation":[{"name":"Department of Human Metabolism at the University of Sheffield and Endocrinology Department at Sheffield Teaching Hospitals NHS Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah","family":"Al\u2010Mohammad","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Science at the University of Sheffield and Cardiology Department at Sheffield Teaching Hospitals NHS Trust Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"INSERM, Centre d'Investigation Clinique and Centre Hospitalier Universitaire, and the Department of Cardiology Nancy University, Universit\u00e9 de Lorraine Nancy France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,12,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192064"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs033"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy\u2010spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"Gasparo M","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20324"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1989.tb03339.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1130"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)91030-7"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200505010-00007"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)91273-9"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000259805.18468.8c"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00054-8"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000067463.13172.EA"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.13.1543"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1993.1066"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.22.17"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.103267"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/08037050701461084"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3280d9434e"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(02)02957-6"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283455ca5"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.4.509"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs257"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.12.018"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.14795"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2011.tb03031.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2011.03.011"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000205831.39339.a5"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc3001.091458"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(96)88542-7"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.47102\/annals-acadmedsg.Hurkan","article-title":"Spironolactone does not prevent restenosis after coronary stenting in humans","volume":"33","author":"Kursaklioglu H","year":"2004","journal-title":"Ann Acad Med Singapore"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2005.03.078"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1481"},{"key":"e_1_2_8_37_1","first-page":"265","article-title":"Two antiatherogenic effects of progesterone on human macrophages; inhibition of cholesteryl ester synthesis and block of its enhancement by glucocorticoids","volume":"84","author":"Cheng W","year":"1999","journal-title":"J Clin Endocrinol Metabol"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01243-8"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000049089"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.10.058"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20762"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq426"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199812000-00009"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.08.021"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2011.04.007"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2011.08.014"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.905"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.09.007"},{"key":"e_1_2_8_49_1","first-page":"33","article-title":"Activity of renin\u2013angiotensin\u2013aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension","volume":"70","author":"Martyniuk TVCI","year":"1998","journal-title":"Ter Arkh"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2010.16"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.094722"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-4-398"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs067"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1510-8"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0393"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-0972-5"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.04.024"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.15.1699"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.02.022"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.10.005"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/sur002"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80282-5"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2004.03146.x"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta14240"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.01.004"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.131342"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs061"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejhf.31","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejhf.31","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T19:16:27Z","timestamp":1746126987000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejhf.31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,14]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/ejhf.31"],"URL":"https:\/\/doi.org\/10.1111\/ejhf.31","archive":["Portico"],"relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,14]]}}}